Among them, core binding factor (CBF) leukemias, represented by t(8;21)(q22;q22)/RUNX1-RUNX1T1 and inv(16)(p13q22)/CBFB-MYH11, are associated with a good prognosis, whereas 11q23/KMT2A (MLL) rearrangements are associated with an intermediate or adverse prognosis, depending on the KMT2A partner gene involved. The gene discussed is CBFB; the disease is leukemia.